PRIMARY AND ACQUIRED DRUG RESISTANCE AMONG RIFAMPICIN RESISTANT TUBERCULOSIS CASES DIAGNOSED ON GENEXPERT

Main Article Content

Muhammad Kashif Munir
Saba Shamim
Muhammad Amer Nazir
Sana Rehman
Ayesha Aftab
Asif Hanif
Muhammad Saqib Saeed

Keywords

GeneXpert, Multidrug resistant, Acquired & Primary resistance, Diagnosis, Susceptibility

Abstract

Drug resistance tuberculosis may be primary or acquired based on treatment history of prior tuberculosis and it is necessary to observe the patterns of resistant among both groups. Purpose of this research was to compare the patterns of drug resistance among primary and acquired drug resistant tuberculosis patients found rifampicin resistant by Xpert MTB/RIF Assay. This cross sectional comparative study was conducted through collaboration among IMBB The University of Lahore and HRI-NIH TB Research Centre Mayo Hospital Lahore during. Pulmonary TB patients provided sputum samples which were processed for Xpert MTB/RIF Assay, smear preparation for Auramin staining, culture and drug susceptibility on Lowenstein Jensen medium. Data of 170 patients was analyzed presently consisting of 86 (50.6%) primary and 84 (49.4%) acquired drug resistance cases, 90 (52.9%) males and 80(47.1%) were females. Presently 133 (78.3%) cases were found to have multidrug resistant tuberculosis. Around 2.9% cases remained susceptible to all drugs while 6.4% cases remained susceptible to rifampicin by drug proportion method. Higher rates of drug resistance as well as multidrug resistant tuberculosis were endorsed in acquired drug resistance cases as compared to primary drug resistance cases primarily diagnosed by Xpert MTB/RIF Assay.

Abstract 66 | PDF Downloads 29

References

1. Global tuberculosis report 2019. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA- 3.0 ICGO.
2. Munir MK, Iqbal R, Shabbir I, Chaudhry K. Factors responsible for failure to initiate tuberculosis treatment among smear positive tuberculosis patients. Pak J Med Res. 2021;51(2):34-37.
3. Muhammad KM, Sana R, Rizwan I. A Need for Tuberculosis Infection Control Measures: A Case Series Study in Pakistan. Asian J Med Biomed.2017;1(1):19-22.
4. Li X, Zhang Y, Shen X, Shen G, Gui X, Sun B, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis. 2007;195(6):864-869. https://doi.org/10.1086/511985
5. Iqbal R, Munir MK, Rehman S, Saeed S. Drug Resistant Tuberculosis: Pattern Seen among Patients Visiting Mayo Hospital, Lahore. Pak J Med Res. 2018;57(4):132-37.
6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U,et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet. 2006;368(9547):1575-1580. doi: 10.1016/S0140-6736(06)69573-1
7. Treatment of tuberculosis: guidelines for national programmes. (2003) World Health Organization Geneva. 3rd edition. WHO/CDS/TB/2003.13.
8. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, Yanova GV, Strelis AK. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis. 2004;39(9):1321-1328. https://doi.org/10.1086/425005
9. Iqbal R, Munir MK, Saeed S, Salam AA, Rehman S, Qadeer E, Khan SU. (2015) Drug resistant tuberculosis among patients in chest unit of Mayo Hospital Lahore. Pak J Chest Med. 2015;19(4):139-145.
10. Saeed M, Ahmad M, Iram S, Riaz S, Akhtar M, Aslam M. GeneXpert technology: A breakthrough for the diagnosis of tuberculous pericarditis and pleuritis in less than 2 hours. Saudi Med J. 2017;38(7):699-705. doi: 10.15537/smj.2017.7.17694.
11. World Health Organization. Xpert MTB/RIF implementation manual: technical and operational ‘how-to’; practical considerations. World Health Organization; 2014.
12. National TB Control Program, Pakistan. Hand book of DR-TB practice. Adopted from WHO 2015 companion handbook. MDR handbook 22.04.2017.cdr. Available from: [https://phkh.nhsrc.pk/sites/default/files/2020-10/Hand%20Book%20of%20DR%20TB%20Practice%20NTCB%202017.pdf]
13. Centre TC. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1960;23(4-5):535. PMC2555609.
14. Saeed N, Ikram N, Shaukat F, Sardar F. Comparison of Auramine Phenol and ZN Staining in Diagnosis of Pulmonary Tuberculosis with GeneXpert MTB/RIF as Gold Standard. J Islamabad Med Dental Coll. 2020;9(3):190-4.
15. Munir MK, Rehman S, Iqbal R, Saeed MS, Aasim M. Comparison of Gene Xpert MTB/RIF assays with conventional standard proportion method for determination of drug susceptibility in multidrug resistant TB suspects. Annals KEMU 2018;24(1):570-576. DOI:10.21649/akemu.v24i1.2335
16. Raoot A, Dev G. Evaluate “Rifampicin Resistance” as Surrogate Marker for Rapid Detection of MDR-TB Using Real-Time PCR Directly on FNAC Samples of Tuberculous Lymphadenitis. Br J Med Med Res. 2015;9(5):1-8. https://doi.org/10.9734/BJMMR/2015/16687
17. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633-2640. DOI: 10.1128/JCM.00553-13
18. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Resp Crit care Med. 2019;200(10):e93-142. DOI: 10.1164/rccm.201909-1874ST
19. Glasauer S, Altmann D, Hauer B, Brodhun B, Haas W, Perumal N. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. PloS one. 2019;14(6):e0217597. doi: 10.1371/journal.pone.0217597
20. Khan S, Khan MA, Nasir SM, Naveed A, Latif A, Javaid A. Factors associated with new and re-treated Multidrug-Resistant Tuberculosis in Khyber Pakhtunkhwa. Pak J Chest Med. 2019;25(2):74-82.

Most read articles by the same author(s)